Recent News

• 09.11.2025 - PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgoTM (SPT-320) in Healthy Volunteers
• 09.11.2025 - PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgoTM (SPT-320) in Healthy Volunteers
• 08.28.2025 - PureTech to Present 2025 Half Year Results
• 08.28.2025 - PureTech to Present 2025 Half Year Results
• 08.28.2025 - PureTech Health plc – Half-Year Report
• 08.28.2025 - PureTech Health plc – Half-Year Report
• 08.21.2025 - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
• 08.21.2025 - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
• 08.18.2025 - Notice of Half-Yearly Results
• 08.18.2025 - Notice of Half-Yearly Results

Recent Filings

• 08.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.28.2025 - EX-99.1 EX-99.1
• 08.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.16.2025 - EX-99.1 EX-99.1
• 07.08.2025 - EX-99.1 EX-99.1